• AZ505: Precision SMYD2 Inhibition for Epigenetic Research

  2026-06-16

  AZ505, a potent and selective SMYD2 inhibitor from APExBIO, empowers researchers to dissect epigenetic regulation and disease mechanisms with high specificity. Its proven efficacy in models of cancer and renal fibrosis enables advanced experimental design, reproducible workflows, and new therapeutic insights.

• Efficient GRO-seq Protocol Enhances Nascent RNA Profiling in

  2026-06-16

  Chen et al. introduce an optimized, cost-effective GRO-seq protocol for bread wheat that integrates an rRNA depletion step, dramatically increasing usable data yield. This approach enables more accessible, high-resolution profiling of nascent transcription in complex plant genomes, with broad implications for transcriptomic research.

• Dual-Action Inhibitors Accelerate p38α MAPK Dephosphorylatio

  2026-06-15

  The referenced study reveals that specific kinase inhibitors not only block p38α MAP kinase activity but also accelerate its dephosphorylation by stabilizing a phosphatase-favored conformation. This dual-action mechanism offers new strategic insights for improving selectivity and efficacy in inflammation and apoptosis research.

• (S)-(+)-Ibuprofen: Precision COX Inhibitor for Inflammation

  2026-06-15

  (S)-(+)-Ibuprofen stands out as the pharmacologically active COX inhibitor, enabling advanced inflammation pathway research and reproducible pain mechanism studies. This article delivers actionable protocols, sustainability insights, and troubleshooting strategies for maximizing (S)-(+)-Ibuprofen’s impact in both cellular and in vivo models.

• Merimepodib (VX-497): Targeting Host Nucleotide Metabolism i

  2026-06-14

  This thought-leadership article explores how Merimepodib (VX-497), a selective oral IMPDH inhibitor, is redefining strategies for translational research in oncology, immunology, and antiviral science. Drawing on mechanistic insights and landmark studies—including recent work demonstrating its suppression of PEDV replication by targeting host nucleotide metabolism—the article provides actionable guidance for experimental design, protocol optimization, and cross-domain innovation. APExBIO’s Merimepodib is spotlighted not merely as a research reagent, but as a strategic enabler for next-generation investigations.

• DiscoveryProbe™ L1023: A Validated Anti-Cancer Compound Libr

  2026-06-13

  The DiscoveryProbe™ Anti-cancer Compound Library (SKU: L1023) is a rigorously validated resource comprising 1,164 bioactive compounds targeting key oncogenic signaling pathways. This L1023 Anti-Cancer Compound Library supports high-throughput screening of anti-cancer agents and pathway-specific drug discovery with robust, peer-reviewed evidence.

• Natural Compounds Target SARS-CoV-2 Protease and Spike: Dock

  2026-06-12

  This study identifies repurposed natural compounds, notably vitamins, as potential inhibitors of SARS-CoV-2 by targeting both the main protease (3CLpro) and the spike protein receptor-binding domain using molecular docking and dynamics simulation. The findings inform ongoing antiviral therapeutics research by highlighting accessible agents for disrupting viral entry and replication.

• Simvastatin (Zocor): Applied Workflows for Lipid and Cancer

  2026-06-12

  Simvastatin (Zocor) from APExBIO provides a multifaceted tool for dissecting cholesterol metabolism and cancer cell fate, with validated protocols for apoptosis, autophagy, and lipid regulation. This guide distills the latest workflows, practical troubleshooting, and novel assay innovations to unlock Simvastatin’s full potential in both cardiovascular and oncology research.

• L1023 Anti-Cancer Compound Library: Mechanistic Insights and

  2026-06-11

  Explore the L1023 Anti-Cancer Compound Library's unique utility for dissecting oncogenic signaling, with a special focus on mechanistic pathway analysis and real-world assay design. Gain in-depth guidance and practical insights not found in other resources.

• Tetrahydromagnolol as a Peripheral CB2 Receptor Agonist: App

  2026-06-11

  Tetrahydromagnolol offers unmatched selectivity and potency for peripheral CB2 receptor research, making it a versatile tool for modeling anti-inflammatory and analgesic mechanisms. Its dual action as a GPR55 antagonist uniquely positions it for dissecting complex GPCR signaling in both inflammation and metastatic cancer models.

• Strategic NF-κB Modulation: QNZ (EVP4593) in Translation

  2026-06-10

  Explore how QNZ (EVP4593) accelerates translational research by precisely targeting the NF-κB pathway. This article combines mechanistic insights with practical guidance for deploying this anti-inflammatory compound in neurodegenerative and inflammatory models, referencing both clinical challenges and the latest experimental advances.

• RG108 (SKU A1913): Reliable DNMT Inhibition for Cancer Resea

  2026-06-10

  This article explores real-world laboratory challenges in epigenetic gene regulation and demonstrates how RG108 (SKU A1913), a DNA methyltransferase inhibitor, delivers reproducible and quantitative solutions. Scenario-driven Q&A blocks guide researchers through experimental design, protocol optimization, and product selection, ensuring robust data for cancer research and cell-based assays.

• Thermal Shift Assays for Ligand Discovery in Bacterial Senso

  2026-06-09

  This review highlights how thermal shift assays (TSA) have enabled the identification of ligands for diverse bacterial sensor proteins. The paper details methodological advances, reliability considerations, and the importance of accurate ligand screening for understanding bacterial signaling, with relevant implications for drug discovery and pathway analysis.

• Strategic Advances in Protease Inhibition for Translational

  2026-06-09

  This thought-leadership article unpacks the mechanistic significance of protease inhibition and connects it to actionable strategies for translational researchers. Drawing on recent peer-reviewed findings and the capabilities of the DiscoveryProbe™ Protease Inhibitor Library, we bridge biological rationale, experimental validation, and clinical relevance. The result is a nuanced, evidence-backed roadmap for accelerating discoveries in apoptosis, cancer, and infectious disease research, setting a new standard beyond conventional product overviews.

• CPI-613 in Tumor Cell Metabolism Studies: Advanced Protocols

  2026-06-08

  CPI-613 (6,8-bis(benzylsulfanyl)octanoic acid) unlocks new frontiers in apoptosis assays and tumor metabolism studies by targeting mitochondrial vulnerabilities unique to cancer cells. This guide delivers advanced workflows, troubleshooting strategies, and actionable insights for translational researchers aiming to dissect chemoresistance and metabolic reprogramming with APExBIO’s validated compound.

15266 records 1/1018 page Next 12345 下5页 Last page